AP Pharma Signs Agreement With Merial

AP Pharma has entered into a license and development agreement with Merial. The license agreement follows a successful research collaboration between the companies.

Under the terms of the new agreement, AP Pharma grants Merial a worldwide, exclusive license to the product for use in treating companion animals (cats and dogs).

Reportedly, AP Pharma will receive an undisclosed upfront payment, development funding and potential future milestones that are in addition to royalties following commercialisation.

Ronald Prentki, president and CEO of AP Pharma, said: “ we seek to expand the application of our Biochronomer technology into the field of veterinary medicine. We are hopeful that, through our efforts with Merial, we will not only provide veterinarians with an important new approach to managing pain in companion animals, but also that this effort will prove to be synergistic with our other pain management programs for humans.”